<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(1)</volume><submitter>Weissler EH</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>Thoracic endovascular aortic repair (TEVAR) has increasingly been used for uncomplicated type B aortic dissection (uTBAD) despite limited supporting data.&lt;h4>Objective&lt;/h4>To assess whether initial TEVAR following uTBAD is associated with reduced mortality or morbidity compared with medical therapy alone.&lt;h4>Design, setting, and participants&lt;/h4>This cohort study included Centers for Medicare &amp; Medicaid Services inpatient claims data for adults aged 65 years or older with index admissions for acute uTBAD from January 1, 2011, to December 31, 2018, with follow-up available through December 31, 2019.&lt;h4>Exposures&lt;/h4>Initial TEVAR was defined as TEVAR within 30 days of admission for acute uTBAD.&lt;h4>Main outcomes and measures&lt;/h4>Outcomes included all-cause mortality, cardi</pubmed_abstract><journal>JAMA cardiology</journal><pagination>44-53</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637274</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection.</pubmed_title><pmcid>PMC9637274</pmcid><pubmed_authors>Weissler EH</pubmed_authors><pubmed_authors>Osazuwa-Peters OL</pubmed_authors><pubmed_authors>Jones WS</pubmed_authors><pubmed_authors>O'Brien SM</pubmed_authors><pubmed_authors>Vekstein AM</pubmed_authors><pubmed_authors>Shalhub S</pubmed_authors><pubmed_authors>Mark DB</pubmed_authors><pubmed_authors>Hardy NC</pubmed_authors><pubmed_authors>Kougias P</pubmed_authors><pubmed_authors>Mussa FF</pubmed_authors><pubmed_authors>Patel MR</pubmed_authors><pubmed_authors>Secemsky EA</pubmed_authors><pubmed_authors>Greiner MA</pubmed_authors><pubmed_authors>Vemulapalli S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection.</name><description>&lt;h4>Importance&lt;/h4>Thoracic endovascular aortic repair (TEVAR) has increasingly been used for uncomplicated type B aortic dissection (uTBAD) despite limited supporting data.&lt;h4>Objective&lt;/h4>To assess whether initial TEVAR following uTBAD is associated with reduced mortality or morbidity compared with medical therapy alone.&lt;h4>Design, setting, and participants&lt;/h4>This cohort study included Centers for Medicare &amp; Medicaid Services inpatient claims data for adults aged 65 years or older with index admissions for acute uTBAD from January 1, 2011, to December 31, 2018, with follow-up available through December 31, 2019.&lt;h4>Exposures&lt;/h4>Initial TEVAR was defined as TEVAR within 30 days of admission for acute uTBAD.&lt;h4>Main outcomes and measures&lt;/h4>Outcomes included all-cause mortality, cardi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-05T12:28:52.094Z</modification><creation>2025-04-05T12:28:52.094Z</creation></dates><accession>S-EPMC9637274</accession><cross_references><pubmed>36334259</pubmed><doi>10.1001/jamacardio.2022.4187</doi></cross_references></HashMap>